These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 1313259)

  • 1. Demonstration of functional compartments of cyclic AMP in rat platelets by the use of phosphodiesterase inhibitors.
    Ashida S; Sakuma K
    Adv Second Messenger Phosphoprotein Res; 1992; 25():229-39. PubMed ID: 1313259
    [No Abstract]   [Full Text] [Related]  

  • 2. 7-Bromo-1,5-dihydro-3,6-dimethylimidazo[2,1-b]quinazolin-2(3H)- one (Ro 15-2041), a potent antithrombotic agent that selectively inhibits platelet cyclic AMP-phosphodiesterase.
    Muggli R; Tschopp TB; Mittelholzer E; Baumgartner HR
    J Pharmacol Exp Ther; 1985 Oct; 235(1):212-9. PubMed ID: 2995647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DN 9693: a phosphodiesterase inhibitor with a platelet membrane effect.
    Jackson C; Ball J; Peel J; Lawry J; Greaves M; Preston FE
    Thromb Haemost; 1989 Apr; 61(2):266-9. PubMed ID: 2546286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective inhibitor of platelet cyclic adenosine monophosphate phosphodiesterase, cilostamide, inhibits platelet aggregation.
    Hidaka H; Hayashi H; Kohri H; Kimura Y; Hosokawa T; Igawa T; Saitoh Y
    J Pharmacol Exp Ther; 1979 Oct; 211(1):26-30. PubMed ID: 226672
    [No Abstract]   [Full Text] [Related]  

  • 5. Effects of a thromboxane synthetase inhibitor and a cAMP phosphodiesterase inhibitor, singly and in combination, on platelet behaviour.
    Sills T; Heptinstall S
    Thromb Haemost; 1986 Jun; 55(3):305-8. PubMed ID: 3018954
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of adenosine on levels of adenosine cyclic 3',5'-monophosphate in human blood platelets in relation to adenosine incorporation and platelet aggregation.
    Haslam RJ; Rosson GM
    Mol Pharmacol; 1975 Sep; 11(5):528-44. PubMed ID: 170501
    [No Abstract]   [Full Text] [Related]  

  • 7. [Pharmacologic value of cyclic nucleotide phosphodiesterase inhibitors].
    Nemoz G; Prigent AF
    Ann Pharm Fr; 1984; 42(2):99-112. PubMed ID: 6091520
    [No Abstract]   [Full Text] [Related]  

  • 8. DN.9693, a phosphodiesterase inhibitor, compared with prostaglandin E1 and prostacyclin in four platelet "function" tests.
    O'Brien JR; Etherington MD; Salmon GP
    Thromb Res; 1988 Apr; 50(1):237-41. PubMed ID: 2840751
    [No Abstract]   [Full Text] [Related]  

  • 9. Phosphodiesterase inhibitors as antiplatelet agents in vascular surgery.
    Kambayashi J; Watase M; Kawasaki T; Shiba E; Sakon M; Mori T; Isaka Y; Kimura K; Kamada T
    Adv Second Messenger Phosphoprotein Res; 1992; 25():383-93. PubMed ID: 1313269
    [No Abstract]   [Full Text] [Related]  

  • 10. Effect of cAMP phosphodiesterase inhibitors on ADP-induced shape change, cAMP and nucleoside diphosphokinase activity of rabbit platelets.
    Lam SC; Guccione MA; Packham MA; Mustard JF
    Thromb Haemost; 1982 Apr; 47(2):90-5. PubMed ID: 6285543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new insight of anti-platelet effects of sirtinol in platelets aggregation via cyclic AMP phosphodiesterase.
    Liu FC; Liao CH; Chang YW; Liou JT; Day YJ
    Biochem Pharmacol; 2009 Apr; 77(8):1364-73. PubMed ID: 19426675
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A potent and selective inhibitor of cyclic AMP phosphodiesterase with potential cardiotonic and antithrombotic properties.
    Alvarez R; Banerjee GL; Bruno JJ; Jones GL; Littschwager K; Strosberg AM; Venuti MC
    Mol Pharmacol; 1986 Jun; 29(6):554-60. PubMed ID: 3012320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of DN-9693, a new metastasis inhibitor, on murine hematogenous metastasis.
    Tanaka NG; Tohgo A; Ogawa H; Osada Y
    Anticancer Res; 1986; 6(4):543-8. PubMed ID: 3019218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of platelet cyclic 3',5'-adenosine-monophosphate phosphodiesterases by pentifylline.
    Stefanovich V
    Arzneimittelforschung; 1975 May; 25(5):740-1. PubMed ID: 170944
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Y-590 (a new pyridazinone derivative), a potent anti-thrombotic agent--II. Inhibition of platelet phosphodiesterase.
    Mikashima H; Nakao T; Goto K; Ochi H; Yasuda H; Tsumagari T
    Thromb Res; 1984 Sep; 35(5):589-94. PubMed ID: 6091293
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anagrelide: a potent and selective inhibitor of platelet cyclic AMP phosphodiesterase enzyme activity.
    Gillespie E
    Biochem Pharmacol; 1988 Jul; 37(14):2866-8. PubMed ID: 2456068
    [No Abstract]   [Full Text] [Related]  

  • 17. Inhibitory effects of DN-9693 on platelet-enhanced tumor cell attachment to cultured endothelium.
    Tohgo A; Tanaka NG; Osada Y
    Invasion Metastasis; 1990; 10(1):1-17. PubMed ID: 2154413
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interactions between prostaglandin E2 and inhibitors of platelet aggregation which act through cyclic AMP.
    Gray SJ; Heptinstall S
    Eur J Pharmacol; 1991 Feb; 194(1):63-70. PubMed ID: 1647965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Control of platelet activation by cyclic AMP turnover and cyclic nucleotide phosphodiesterase type-3.
    Feijge MA; Ansink K; Vanschoonbeek K; Heemskerk JW
    Biochem Pharmacol; 2004 Apr; 67(8):1559-67. PubMed ID: 15041473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic antiplatelet effect of ridogrel, a combined thromboxane receptor antagonist and thromboxane synthase inhibitor, and UDCG-212, a cAMP-phosphodiesterase inhibitor.
    Hoet B; Arnout J; Deckmyn H; Vermylen J
    Thromb Haemost; 1993 Nov; 70(5):822-5. PubMed ID: 8128441
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.